|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.454 EUR | -2.57% |
|
-6.19% | -33.45% |
| 04/12 | Evotec's Partner Bayer Starts Mid-stage Study of Genetic Kidney Disease Drug | MT |
| 04/12 | Bayer Starts Phase IIa Study for Treatment of Patients with Alport Syndrome | CI |
0.wMwI5orYCi8HpE4xH00BQPOnbb8-H8JzdfyXo_avgFk.mKtn3qfsemw23RhJLH1sc771C9ZIUps0MKzayML88Bu1k36NzKo-HU2VIQ~1b73d8bd7a3362eb3bbe15d1a489cd4c
- Stock Market
- Equities
- EVT Stock
- Charts Evotec SE
- News Chart
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition